Advertisement

Search Results

Advertisement



Your search for it matches 15612 pages

Showing 1301 - 1350


integrative oncology

Psilocybin

The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Yen Nien (Jason) Hou, PharmD, DiplOM, LAc, and Jyothirmai Gubili, MS, focus on ...

From a Sleepy Town in Pakistan, Seema A. Khan, MD, MPH, Emerges as a Leader in Surgical Oncology

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Seema A. Khan, MD, MPH, Professor of Breast Cancer Surgery at Northwestern Medicine, Feinberg School of Medicine. Along with her surgical and academic pursuits, Dr. Khan is an active...

National Inventors Hall of Fame Recognizes Jennifer Doudna, PhD; Emmanuelle Charpentier, PhD; and Angela Hartley Brodie, PhD

The National Inventors Hall of Fame (NIHF) recognizes the enduring legacies of exceptional U.S. patent holders on an annual basis. On October 26, 2023, three female inductees will be recognized for their extraordinary contributions to cancer care and clinical research. Biochemist Jennifer...

breast cancer

Circulating Tumor DNA Identified in Breast Milk From Women With Breast Cancer: First Results Published

Breast milk from women with breast cancer who were diagnosed during pregnancy or postpartum contains circulating tumor DNA (ctDNA), according to researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. The investigators noted that ctDNA can be detected through liquid biopsy in...

geriatric oncology
issues in oncology

New Poll Weighs Necessity of Life Expectancy in Cancer Screening Guidelines

A majority of older adults may disagree with the idea of using life expectancy as part of cancer screening guidelines, according to a new University of Michigan National Poll on Healthy Aging. Background The response goes against a trend in guidelines aimed at helping health-care providers decide...

lung cancer

Ilias Houda, MD, PhD Candidate, on Results of an EORTC Survey on NSCLC Resectability

Ilias Houda, MD, PhD Candidate, of Amsterdam University Medical Centers, discusses the differing opinions of thoracic surgeons when it comes to resection for stage III non–small cell lung cancer (NSCLC). The international EORTC survey showed there is no consensus, although respondents were more...

multiple myeloma
issues in oncology

Diabetes May Be Linked to Lower Survival Among Patients With Multiple Myeloma; Survival Outcomes May Be Race-Dependent

Patients with multiple myeloma who also have diabetes may experience worse overall survival outcomes compared with patients who don’t have diabetes, according to a recent study published by Shah et al in Blood Advances. The new findings demonstrated that the differences in survival may be dependent ...

Liquid Biopsy May Help Identify Patients With NSCLC Who Could Benefit From Radiation Therapy

Liquid biopsy may help determine which patients with oligometastatic non–small cell lung cancer (NSCLC) with metastases may be most likely to benefit from targeted, high-dose radiation therapy rather than drug-based therapy, according to findings simultaneously published by Semenkovich et al in npj ...

breast cancer
issues in oncology
palliative care

Racial and Ethnic Minority Patients With Breast Cancer May Be Less Likely to Receive Palliative Care Than White Patients

Despite a steady increase in palliative care utilization from 2004 to 2020, racial and ethnic minority patients with metastatic breast cancer may be less likely to receive palliative care compared with non-Hispanic White patients with the disease, according to new findings presented by Freeman et...

supportive care
pain management
palliative care
symptom management

Using Recent Diagnostic Scans May Cut Time to Treatment for Patients Needing Urgent Palliative Radiotherapy

Using previously taken diagnostic computed tomography (CT) scans in place of CT simulation scans to plan simple palliative radiation treatments may substantially reduce the time spent waiting for urgent treatment, improving the patient experience, a new study suggests. Patients who may benefit from ...

gynecologic cancers

Sexual Activity and Vaginal Dilation Associated With Fewer Side Effects After Chemoradiation for Cervical Cancer

People who engage in sexual activity or vaginal dilation after chemoradiation for cervical cancer are at lower risk for long-term side effects, according to a new study from researchers in Austria. Findings of the EMBRACE study were presented by Kirchheiner et al at the 2023 American Society for...

lung cancer

The New Era of Perioperative Therapy in Non–Small Cell Lung Cancer

Recent developments in surgery and therapeutics are changing the perioperative approach to non–small cell lung cancer (NSCLC). These advances were discussed at the 2023 Debates and Didactics in Hematology and Oncology conference, sponsored by Emory University, by Jennifer W. Carlisle, MD, Assistant ...

gynecologic cancers
issues in oncology

Liquid Biopsies May Be Predictive of Cancer Recurrence Following Chemoradiation in Patients With Cervical Cancer

Two liquid biopsy tests designed to detect the human papillomavirus (HPV) in the blood may accurately identify patients at high risk of cervical cancer recurrence following the completion of chemoradiation, according to new findings presented by Han et al at the 2023 American Society for Radiation...

prostate cancer
issues in oncology

Precision Medicine Navigators May Increase Genomic Testing Rates Among Black Patients With Prostate Cancer

The presence of precision medicine navigators may increase the likelihood that patients with prostate cancer, especially Black patients, will receive genomic testing that may help predict the severity of their disease and guide treatment, according to findings presented by Allen et al at the 2023...

breast cancer

Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation: FABREC Trial

In a first-of-its-kind study, patients with breast cancer who underwent implant-based breast reconstruction immediately following a mastectomy reported that getting fewer, higher doses of radiation was just as effective as standard radiation, did not increase side effects, and saved them time and...

kidney cancer

Stereotactic Radiotherapy for Patients With Primary RCC Unsuitable for Surgery: FASTRACK II

Older adults diagnosed with kidney tumors that are not suitable for surgery may benefit from targeted, high-dose radiation, a new study from Australian and Dutch researchers suggests. A multi-institutional phase II study—TransTasman Radiation Oncology Group (TROG) FASTRACK II—found 100% local...

prostate cancer

SBRT vs Standard Radiotherapy for Localized Prostate Cancer: 5-Year Analysis of PACE B

People with intermediate-risk, localized prostate cancer may be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggested. The findings, which...

solid tumors
issues in oncology

Long-Term Low-Grade Intestinal Inflammation May Be Prevalent Among Patients Who Have Undergone Radiotherapy

Researchers have found that low-grade intestinal inflammation may be a side effect of radiotherapy, according to a recent study published by Devarakonda et al in eBioMedicine. Background Radiotherapy is often necessary to cure cancer or slow down cancer development. Although today’s radiotherapies...

immunotherapy
lung cancer
breast cancer
skin cancer
gastrointestinal cancer

Neoadjuvant Immune Checkpoint Blockade May Be Effective Across Multiple Cancer Types

Neoadjuvant immunotherapy may be effective prior to surgery in multiple types of cancers, according to a recent study published by Topalian et al in Cancer Cell. Background Neoadjuvant immune checkpoint blockades have been a rapidly growing area of research and are currently being tested across...

issues in oncology

The Future Priorities of the National Cancer Institute

Fifty-two years ago, President Richard Nixon signed the National Cancer Act of 1971 into law, which established the National Cancer Institute (NCI) in its current form. At the time, the budget was $1.6 billion. Today, it is $7.8 billion, $4.5 billion less than the amount needed to keep up with...

solid tumors
issues in oncology

Unconscious Gender Biases and Discrimination Lead to Suboptimal Care for Women

Gender inequalities and discrimination may adversely impact women’s rights and opportunities to avoid cancer risk factors and impede their ability to seek and obtain timely diagnoses and quality cancer care, according to The Lancet Commission on Women, Power, and Cancer published by Ginsburg et al...

breast cancer
issues in oncology

Using Whole-Body Imaging Agent to Predict Response to Treatment in HER2-Positive Metastatic Breast Cancer

The novel imaging agent gallium (Ga)-68–ABY-025 may help to predict early metabolic response to HER2-targeted treatment in patients with HER2-positive metastatic breast cancer, according to a recent study published by Alhuseinalkhudhur et al in The Journal of Nuclear Medicine. These findings...

prostate cancer
genomics/genetics

Mutations in 11 Genes May Be Associated With Aggressive Prostate Cancer

Researchers have singled out mutations in 11 genes associated with aggressive types of prostate cancer, according to a novel study published by Darst et al in JAMA Oncology. The new findings may lead to improvements in diagnosis and treatment. Background Currently, oncologists use genetic tests to...

lung cancer
genomics/genetics
immunotherapy

Do Checkpoint Inhibitors Show Benefit in EGFR-Mutated NSCLC After Progression?

In patients with advanced non–small cell lung cancer (NSCLC) harboring EGFR mutations, the role of immune checkpoint inhibitors following disease progression with tyrosine kinase inhibitors has been unclear. Several studies reported at the International Association for the Study of Lung Cancer 2023 ...

colorectal cancer
supportive care

High-Intensity Training May Reduce the Risk of Colorectal Cancer in Patients With Lynch Syndrome

Regular and intense aerobic exercise may be effective at reducing the risk of colorectal cancer in patients with Lynch syndrome by improving the immune system's ability to detect and remove potentially harmful cells, according to a novel study published by Deng et al in Clinical Cancer Research....

MD Anderson and Ochsner Health Partner to Create First Fully Integrated Cancer Program in Louisiana

The University of Texas MD Anderson Cancer Center and New Orleans–based Ochsner Health recently announced a partnership to create Ochsner MD Anderson Cancer Center in southeastern Louisiana. Patients with cancer in the region now will have access to treatments that are among the most advanced in...

City of Hope Receives $32.3 Million From the California Institute for Regenerative Medicine to Advance Innovative Therapies

Researchers at City of Hope were awarded $32.3 million from the California Institute for Regenerative Medicine (CIRM) to support three novel phase I clinical trials evaluating innovative cell and gene therapies for patients with HIV, acute myeloid leukemia (AML), and severe aplastic anemia. Beckman ...

sarcoma
global cancer care

Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma

The management of sarcoma presents several challenges because of its rarity and diverse subtypes, making accurate diagnosis and specialized treatment crucial. A multidisciplinary approach involving various experts from different cancer specialties is the optimal strategy to improve survival and...

lymphoma

Finding a New Life Purpose After Cancer

In the summer of 2012, I was living my dream. At 28 years old, I had gone from an impoverished childhood in South Central Los Angeles to the high life in the city of Los Angeles. Unable to afford to go to college, an after-school program helped launch me into a career in the hospitality industry. I ...

global cancer care

Surgical Oncologist Héber Salvador, MD, PhD, Offers an Inside Look at Cancer Care in Brazil, Complete With Its Diversity and Inequities

In this installment of The ASCO Post’s Global Oncology series, Guest Editor Chandrakanth Are, MBBS, MBA, FRCS, FACS, the Jerald L. & Carolynn J. Varner Professor of Surgical Oncology & Global Health at the University of Nebraska Medical Center, Omaha, spoke with Héber Salvador, MD, PhD,...

ACS Funds UAMS Study to Understand Treatment Resistance in Pancreatic Cancer

Adam Wolfe, MD, PhD, a radiation oncologist at the University of Arkansas for Medical Sciences (UAMS) Winthrop P. Rockefeller Cancer Institute, has received a $583,200 grant from the American Cancer Society (ACS) to study radiation resistance in pancreatic cancer, a lethal disease with the highest...

From Texas to Sweden, Medical Oncologist Gil Morgan, MD, Enjoys Connecting the Cancer Community

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Gil Morgan, MD, a clinical oncologist formerly at the Division of Medical and Radiation Oncology at Skåne University Hospital, Lund, Sweden and now full-time Director of the OncoAlert...

breast cancer
issues in oncology

Particulate Matter Concentrations and Incidence of Breast Cancer

Investigators have found that residing in areas with high levels of particulate air pollution may be associated with an increased risk of developing breast cancer, according to a recent study published by White et al in the Journal of the National Cancer Institute.   Background Particulate matter...

integrative oncology

SIO and ASCO Partner to Develop Integrative Oncology Care Recommendations for Anxiety and Depression in Patients With Cancer

The Society for Integrative Oncology (SIO) and ASCO have partnered to develop a new guideline on integrative oncology care of symptoms of anxiety and depression in adults with cancer. The guideline reviews the evidence for a range of integrative approaches, including mindfulness-based...

ASCO Participates in President’s Cancer Panel

ASCO joined the President’s Cancer Panel on September 7, 2023, to highlight the numerous ways ASCO is working to advance the National Cancer Plan and achieve President Biden’s Cancer Moonshot goal of “ending cancer as we know it.” This all-day, virtual event was the first public meeting in support...

issues in oncology
solid tumors

ASCO Releases Rapid Recommendation Update on Use of Olanzapine to Treat Cancer-Related Cachexia

ASCO recently released a new rapid recommendation update that addresses the use of olanzapine to treat cancer-related cachexia, a topic originally addressed in its 2020 guideline on the management of cancer cachexia in adults with advanced cancer.1,2 At that time, there was insufficient evidence to ...

multiple myeloma

Accelerated Approval Granted for Talquetamab-tgvs in Treatment of Relapsed or Refractory Multiple Myeloma

On August 9, 2023, the bispecific GPRC5D (G protein–coupled receptor, class C, group 5)-directed CD3 T-cell engager talquetamab-tgvs was granted accelerated approval by the U.S. Food and Drug Administration for treatment of adults with relapsed or refractory multiple myeloma who have received at...

prostate cancer

Fixed-Dose Niraparib and Abiraterone Plus Prednisone in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

On August 11, 2023, the fixed-dose combination of the PARP inhibitor niraparib and the CYP17 inhibitor abiraterone acetate plus prednisone was approved for patients with deleterious or suspected deleterious BRCA-mutated castration-resistant prostate cancer, as determined by a U.S. Food and Drug...

New Assistant Program Director for Complex General Surgical Oncology Fellowship at Fox Chase Cancer Center

Andrea Porpiglia, MD, MSc, FACS, Associate Professor in the Department of Surgical Oncology at Fox Chase Cancer Center, has been promoted to Assistant Program Director for the Complex General Surgical Oncology Fellowship. “Dr. Porpiglia has been an instrumental part of teaching the next generation ...

skin cancer

Ipilimumab Plus Nivolumab May Improve Outcomes in Refractory Metastatic Melanoma, Study Suggests

Researchers have discovered that the combination of the CTLA-4 inhibitor ipilimumab and the PD-1 inhibitor nivolumab may be an effective second-line therapy in patients with PD-1 blockade–refractory metastatic melanoma, according to a recent study conducted by the SWOG Cancer Research Network and...

solid tumors
issues in oncology

Highlights in Cancer and Aging From the 2023 ASCO Annual Meeting

The 2023 ASCO Annual Meeting again demonstrated the Society’s commitment to improving cancer care for all older adults. Pertinent questions related to treatment and management in this population were addressed in educational and oral abstract sessions, clinical science symposia, and case-based...

lymphoma

Understanding the Treatment of Waldenström’s Macroglobulinemia

Waldenström’s macroglobulinemia is a rare and incurable low-grade B-cell lymphoproliferative disease defined by specific genotypic subtypes that have implications for treatment response and long-term outcomes. Treatment—and there is no established standard—is mainly focused on controlling symptoms...

issues in oncology

Distributing Scarce Cancer Drugs Legally and Ethically

During the COVID-19 pandemic, many medical specialties became familiar with supply chain interruptions resulting in drug, equipment, and personnel scarcity. Intensive care unit beds, staff, and essential medicines were at times in short supply. The federal government, individual states, and...

issues in oncology

Accelerating Progress Against Cancer and Other Life-Threatening Diseases

Cancer—and the quest to accelerate more effective treatments and potential cures for all life-threatening diseases—has perhaps shaped the life of financier Michael Milken more than his legendary career on Wall Street. In the early 1970s, Mr. Milken’s mother-in-law was diagnosed with metastatic...

multiple myeloma
issues in oncology

The Immune System May Play Vital Role in Remission Duration Among Patients With Multiple Myeloma

Researchers have uncovered the vital role that the immune system may play in determining the duration of remission and progression-free survival in patients with multiple myeloma, according to a recent study published by Coffey et al in Nature Communications. The new findings suggested that the...

colorectal cancer

Colorectal Cancer Screening: Major Communication Gap in the Clinical Setting

According to the American Cancer Society, colorectal cancer is the second-leading cause of cancer-related death in the United States. In 2023, the disease is expected to cause an estimated 52,550 deaths. Studies show that receiving a clinician recommendation is the strongest and most consistent...

leukemia

Retrospective Study Reports Tyrosine Kinase Inhibitor Used in CML Associated With Nephrotoxicity

Investigators reported that the tyrosine kinase inhibitor dasatinib, commonly used to treat chronic myeloid leukemia (CML), was associated with nephrotoxicity in 10% of 32 patients with CML being treated with dasatinib in a multicenter, retrospective clinical study conducted to determine the...

breast cancer

ctDNA Identified in Breast Milk From Women With Breast Cancer

Breast milk from women with breast cancer who were diagnosed during pregnancy or postpartum may contain circulating tumor DNA (ctDNA), according to researchers at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. The investigators noted that ctDNA can be detected through liquid biopsy in ...

issues in oncology

Study Examines Disparities in Access to Cancer Care Among Non–English-Speaking Patients in the United States

Researchers have revealed that non–English speakers who seek information from hospitals across the United States may face a concerning lack of access to cancer care services, according to a new study published by Chen et al in JNCCN–Journal of the National Comprehensive Cancer Network. Background...

hematologic malignancies

FDA Approves Momelotinib for Patients With Myelofibrosis and Anemia

On September 15, the U.S. Food and Drug Administration (FDA) approved momelotinib (Ojjaara) for the treatment of intermediate- or high-risk myelofibrosis, including primary myelofibrosis or secondary myelofibrosis (post–polycythemia vera and post–essential thrombocythemia), in adults with anemia....

Advertisement

Advertisement




Advertisement